Related Experiment Video
Updated: Jun 17, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which
1Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA. cbenes@bidmc.harvard.edu
Abstract:
It is becoming increasingly apparent that cancer drug therapies can only reach their full potential through appropriate patient selection. Matching drugs and cancer patients has proven to be a complex challenge, due in large part to the substantial molecular heterogeneity inherent to human cancers. This is not only a major hurdle to the improvement of the use of current treatments but also for the development of novel therapies and the ability to steer them to the relevant clinical indications. In this commentary we discuss recent studies from Kuo et al., published this month in BMC Medicine, in which they used a panel of cancer cell lines as a model for capturing patient heterogeneity at the genomic and proteomic level in order to identify potential biomarkers for predicting the clinical activity of a novel candidate chemotherapeutic across a patient population. The findings highlight the ability of a 'systems approach' to develop a better understanding of the properties of novel candidate therapeutics and to guide clinical testing and application.See the associated research paper by Kuo et al: http://www.biomedcentral.com/1741-7015/7/77.
Insights
Patient selection is key for cancer drug efficacy. A systems approach using cell lines identified biomarkers to predict treatment response in heterogeneous cancers.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Cancer drug effectiveness is limited by patient heterogeneity.
- Identifying predictive biomarkers for novel chemotherapeutics is challenging.
Discussion:
- Kuo et al. utilized a cancer cell line model to simulate patient molecular heterogeneity.
- Genomic and proteomic profiling aimed to identify biomarkers for a novel chemotherapeutic.
- A systems approach enhances understanding of drug properties and clinical application.
Key Insights:
- Cancer cell line panels can model patient heterogeneity.
- Biomarker discovery is crucial for personalized cancer therapy.
- Systems biology aids in predicting drug activity.
Outlook:
- This approach can guide clinical trial design and patient stratification.
- It facilitates the development of targeted cancer therapies.
- Improved patient selection will maximize therapeutic potential.
